ArticleJournal of inflammation research2026
IL-17RA Promotes Cigarette Smoke-Induced Alveolar Epithelial Cell Pyroptosis in COPD via Dual Activation of the NLRP3/Caspase1/GSDMD and NF-κB/GSDME Pathways.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pyroptosis in chronic obstructive pulmonary disease: Beyond the canonical NLRP3/Caspase-1/GSDMD pathway.Immunologic research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) leads to persistent and irreversible airflow limitation due to lung tissue inflammation. Pyroptosis is closely involved in the pathogenesis of COPD and participates in the release of inflammatory factors. IL-17RA is a key receptor for IL-17A; however, the impact of IL-17RA on pyroptosis requires further investigation. Methods: This study elucidates the promoting effect of IL-17RA on the progression of COPD by constructing IL-17RA alveolar type II (AT2) epithelial cell-specific knockout animal models and knockdown models of IL-17RA in AT2 epithelial cells. The process of cellular pyroptosis was observed through transmission electron microscopy. Molecular biology techniques and functional experiments were conducted both in vivo and in vitro to validate the activation of canonical and non-canonical pyroptosis pathways by IL-17RA. Results: Our research findings indicate that the specific knockout of IL-17RA significantly alleviates damage to alveolar epithelial cells in a mouse model exposed to cigarette smoke, thereby delaying the progression of COPD in these mice. In this model, the absence of IL-17RA inhibits pyroptosis in cells and reduces the expression of proteins associated with pyroptosis. In the AT2 cell lines line, the knockdown of IL-17RA significantly suppresses the CSE-induced NLRP3/Caspase1/GSDMD and NFκB/GSDME pathways, thereby mitigating the occurrence of pyroptosis. In the AT2 cell lines line, IL-17A binds to IL-17RA, triggering the NLRP3/Caspase1/GSDMD pathway without activating the NFκB/GSDME pathway. Conclusion: Our research emphasizes that IL-17RA promotes pyroptosis by activating the NLRP3/Caspase1/GSDMD and NFκB/GSDME pathways, and is involved in the progression of COPD, providing a promising target for the prevention and intervention of COPD in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.